Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sight Sciences, Inc. before investing.

In this article, we go over a few key elements for understanding Sight Sciences, Inc.’s stock price such as:

• Sight Sciences, Inc.’s current stock price and volume
• Why Sight Sciences, Inc.’s stock price changed recently
• Upgrades and downgrades for SGHT from analysts
• SGHT’s stock price momentum as measured by its relative strength

About Sight Sciences, Inc. (SGHT)

Before we jump into Sight Sciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Want to learn more about Sight Sciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sight Sciences, Inc..

Sight Sciences, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:44 PM, CST, Sight Sciences, Inc.’s stock price was $3.810.

Sight Sciences, Inc. is down 2.56% from its previous closing price of $3.910.

During the last market session, Sight Sciences, Inc.’s stock traded between $3.800 and $3.900. Currently, there are approximately 53.08 million shares outstanding for Sight Sciences, Inc..

Sight Sciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sight Sciences, Inc. Stock Price History

Sight Sciences, Inc.’s (SGHT) price is currently up 1.06% so far this month.

During the month of April, Sight Sciences, Inc.’s stock price has reached a high of $3.960 and a low of $3.378.

Over the last year, Sight Sciences, Inc. has hit prices as high as $9.236 and as low as $2.400. Year to date, Sight Sciences, Inc.’s stock is down 51.95%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sight Sciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there were 2 analysts who downgraded Sight Sciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Sight Sciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sight Sciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Sight Sciences, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sight Sciences, Inc. (SGHT) by visiting AAII Stock Evaluator.

Relative Price Strength of Sight Sciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Sight Sciences, Inc. has a weighted four-quarter relative price strength of 5.13%, which translates to a Momentum Score of 68 and is considered to be Strong.

Want to learn more about how Sight Sciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sight Sciences, Inc. Stock Price: Bottom Line

As of April 16, 2026, Sight Sciences, Inc.’s stock price is $3.810, which is down 2.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sight Sciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.